News & Updates
Filter by Specialty:
Cilta-cel a new Soc for lenalidomide-refractory MM?
In patients with lenalidomide-refractory multiple myeloma (MM), a single infusion of ciltacabtagene autoleucel (cilta-cel), a dual-binding BCMA*-directed chimeric antigen receptor (CAR) T-cell therapy, improved progression-free survival (PFS) compared with standard of care** (SoC), according to the phase III CARTITUDE-4 trial.
Cilta-cel a new Soc for lenalidomide-refractory MM?
26 Jul 2023
Donanemab puts brakes on Alzheimer’s disease progression
In the treatment of individuals with early symptomatic Alzheimer's disease and amyloid and tau pathology, the immunoglobulin G1 monoclonal antibody donanemab helps slow clinical progression, according to the results of the phase III TRAILBLAZER-ALZ 2 study.
Donanemab puts brakes on Alzheimer’s disease progression
26 Jul 2023
Minimal monitoring feasible in HCV patients on SOF/VEL
Minimal monitoring is feasible in patients with active hepatitis C virus (HCV) infection treated with sofosbuvir/velpatasvir (SOF/VEL), with high rates of sustained virologic response (SVR) reported, including in patients with novel HCV subtypes, according to new data from the phase IV MINMON study presented at IDDF 2023.
Minimal monitoring feasible in HCV patients on SOF/VEL
26 Jul 2023
SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19
Administration of booster doses of mRNA-based vaccines provide protection against COVID-19 and its adverse outcomes in patients with cancer who are actively receiving treatment as well as in cancer survivors, as shown in a study from Singapore.
